Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.61 NOK | -3.20% | +1.64% | -36.40% |
Sales 2024 * | 157M 14.4M | Sales 2025 * | 190M 17.41M | Capitalization | 4.59B 421M |
---|---|---|---|---|---|
Net income 2024 * | -613M -56.21M | Net income 2025 * | -735M -67.4M | EV / Sales 2024 * | 21.2 x |
Net cash position 2024 * | 1.25B 115M | Net cash position 2025 * | 1.01B 92.53M | EV / Sales 2025 * | 18.9 x |
P/E ratio 2024 * |
-7.55
x | P/E ratio 2025 * |
-6.77
x | Employees | 172 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55% |
Latest transcript on Nykode Therapeutics
1 day | -3.20% | ||
1 week | +1.64% | ||
Current month | +1.80% | ||
1 month | -0.44% | ||
3 months | -20.41% | ||
6 months | -27.34% | ||
Current year | -36.40% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 47 | 06-12-31 | |
Michael Engsig
CEO | Chief Executive Officer | - | 07-02-28 |
Harald Gurvin
DFI | Director of Finance/CFO | 49 | 21-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | - |
Director/Board Member | 64 | - | |
Director/Board Member | - | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 0 M€ | -2.11% | - | |
0.00% | 0 M€ | -2.79% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 13.61 | -3.20% | 733 185 |
24-05-07 | 14.06 | +0.57% | 473,350 |
24-05-06 | 13.98 | +1.01% | 839,911 |
24-05-03 | 13.84 | +3.36% | 772,787 |
24-05-02 | 13.39 | +0.15% | 492,249 |
Real-time Oslo Bors, May 08, 2024 at 10:45 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.40% | 422M | |
+3.73% | 106B | |
+7.02% | 23.47B | |
-14.67% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.45% | 16.78B | |
+5.18% | 14.41B | |
+36.55% | 12.86B | |
+326.06% | 8.78B |
- Stock Market
- Equities
- VACC Stock